{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:55:40Z","timestamp":1790873740569,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Nonsteroidal anti\u2010inflammatory drugs (NSAIDs) have been associated with decreased risk of gastric, colorectal, and breast cancer. However, the impact of NSAIDs on the risk of melanoma has been inconsistent. The authors evaluated the association between NSAID use and cutaneous melanoma risk in the Women's Health Initiative (WHI) Observational Study (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>At study entry, use of aspirin (acetylsalicylic acid [ASA]) and nonaspirin NSAIDs was assessed among 59,806 postmenopausal Caucasian women ages 50 to 79 years. Cox proportional hazards models were constructed after adjusting for participant skin type, sun exposure history, and medical indications for NSAID use among other confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>During a median follow\u2010up of 12 years, 548 incident melanomas were confirmed by medical review. Women who used ASA had a 21% lower risk of melanoma (hazard ratio, 0.79; 95% confidence interval, 0.63\u20100.98) relative to nonusers. Increased duration of ASA use (&lt;1 year, 1\u20104 years, and \u22655 years) was associated with an 11% lower risk of melanoma for each categorical increase (<jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub> = .01), and women with \u22655 years of use had a 30% lower melanoma risk (hazard ratio, 0.70; 95% confidence interval, 0.55\u20100.94). In contrast, use of non\u2010ASA NSAIDs and acetaminophen were not associated with melanoma risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Postmenopausal women who used ASA had a significantly lower risk of melanoma, and longer duration of ASA use was associated with greater protection. Although this study was limited by the observational design and self\u2010report of NSAID use, the findings suggest that ASA may have a chemopreventive effect against the development of melanoma and warrant further clinical investigation. Cancer 2013. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27817","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T04:17:53Z","timestamp":1363148273000},"page":"1562-1569","source":"Crossref","is-referenced-by-count":75,"title":["Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women"],"prefix":"10.1002","volume":"119","author":[{"given":"Christina A.","family":"Gamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Swetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia L.","family":"Stefanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Spaunhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh A.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sturgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Y.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"issue":"5","key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaad.2011.04.032","article-title":"Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992\u20102006","volume":"65","author":"Jemal A","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.09.012"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e328339648c"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61543-7"},{"key":"e_1_2_6_6_2","first-page":"6096","article-title":"Breast cancer and nonsteroidal anti\u2010inflammatory drugs: prospective results from the Women's Health Initiative","volume":"63","author":"Harris RE","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60243-9"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.112"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32831d7f52"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000194430.77643.a0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208169"},{"key":"e_1_2_6_12_2","first-page":"655","article-title":"Inverse association of non\u2010steroidal anti\u2010inflammatory drugs and malignant melanoma among women","volume":"8","author":"Harris RE","year":"2001","journal-title":"Oncol Rep"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.201"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.58"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.47"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn154"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk132"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00078-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1907"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1047-2797(03)00042-5"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0652"},{"key":"e_1_2_6_22_2","unstructured":"National Institutes of Health. Women's Health Initiative. Form 44\u2014Current Medications. Available at:https:\/\/cleo.whi.org\/studydoc\/Central%20Forms\/F044.pdf. Accessed July 28 2012."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-011-9766-z"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.016"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-006-0091-x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.5967"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk200"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283107df7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61720-0"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62110-1"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61049-0"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70035-X"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn363"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn362"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27817","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:58:54Z","timestamp":1760291934000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27817"}},"subtitle":["The Women's Health Initiative"],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,4,15]]}},"alternative-id":["10.1002\/cncr.27817"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27817","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,11]]}}}